A Multicenter, Open-label, Randomized, Event-driven Study to Assess Efficacy, Safety and Pharmacokinetics of Macitentan Versus Standard of Care in Children With Pulmonary Arterial Hypertension
Latest Information Update: 04 Sep 2024
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Pharmacokinetics; Registrational; Therapeutic Use
- Acronyms TOMORROW
- Sponsors Actelion Pharmaceuticals
- 17 Jul 2024 Status changed from recruiting to active, no longer recruiting.
- 23 Apr 2024 Planned End Date changed from 29 Feb 2024 to 31 Dec 2024.
- 01 Feb 2024 Planned End Date changed from 8 Sep 2024 to 29 Feb 2024.